Safety and Intracranial Activity of Adagrasib in Patients With KRAS^G12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series

JCO Precis Oncol. 2024 Feb:8:e2300447. doi: 10.1200/PO.23.00447.

Authors

Ezra Bernstein¹, Jia Luo², Kaiwen Wang³, Marcelo V Negrao⁴, Pasi A Jänne², Joshua K Sabari⁵

Affiliations

¹ Langone Department of Internal Medicine, New York University, New York, NY.
² Lowe Center for Thoracic Oncology, Dana-Faber Cancer Institute, Boston, MA.
³ Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁵ Perlmutter Cancer Center, New York University Langone Health, New York, NY.

No abstract available

MeSH terms

Acetonitriles
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Piperazines*
Proto-Oncogene Proteins p21(ras)
Pyrimidines*

Substances

adagrasib
Proto-Oncogene Proteins p21(ras)
Acetonitriles
KRAS protein, human
Piperazines
Pyrimidines